Financing will allow company’s development of DNA synthesis chip technology to commercial scale
News
EU approves AstraZeneca Forxiga for use across the EU
Milestone therapy concerns the treatment of patients with symptomatic chronic heart failure
Kidney Cancer UK makes NICE plea
Charity highlights the need to find kidney cancer early and for better guidance among doctors
Alvotech and Advanz link-up for Xolair drive
Alvotech will be responsible for supply and Advanz will oversee commercialisation of biosimilar
PharmaTimes launches Clinical Researcher of the Year – the Americas 2023
PharmaTimes announces the launch of the 2023 event and hopes to see returning contestants from previous years as well as some new faces
Cambridge Cognition and Aardex collaborate to boost decentralised clinical trials
Partnership involves the study of real-time patient data and identification of adherence issues
Green light for AbbVie’s Crohn’s disease therapy Rinvoq
MHRA approval for Rinvoq which treats adults with moderate to severely active Crohn’s Disease
Endevica Bio and Orbit Discovery unite to boost cachexia therapeutics
The central focus of the agreement is to establish peptide hits from selected library populations
Bill & Melinda Gates Foundation funding for MIP Discovery
Boost concerns rapid deployment of novel detection reagents for testing in low to middle-income countries
BaseCure collaborates with Aptamer Group to boost gene therapies
Binders will establish cell types and delivery vehicles may increase uptake of the siRNA therapy
Vital NICE nod for Jazz’s Epidyolex
UK-wide therapy for patients who have seizures linked to tuberous sclerosis complex
Sanofi’s efanesoctocog alfa may be game-changer for haemophilia A patients
Phase 3 study demonstrated that efanesoctocog alfa met both primary and secondary endpoints
AlzeCure’s neuropathic pain candidate study reaches crucial phase
Research concerns ACD440 – a non-opioid drug which treats peripheral neuropathic pain
Medicines policy may be halting Government’s drive for growth
Lilly is calling for Government to freeze the statutory scheme repayment rate for 2023
Milestone product launch for Kelso Pharma
Acepiro tablets for respiratory diseases will be available across the UK prescription market
